Skip to main content
glpverdict
Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content
HomeGLP-1Which GLP-1 for people with a BMI of 40 or higher

Evidence review · Drug selection

The best GLP-1 for BMI 40+: severe obesity and the surgery question

Medically reviewed by Jane Novak, MD, MPH, MD, MPH · Endocrinology · Internal Medicine 13 min read Fact checked Editorial integrityUpdated Jul 18, 2026

The honest verdict

At BMI 40+, tirzepatide (Zepbound) has the strongest weight-loss evidence and is the usual first choice. But the honest framing is that medication and bariatric surgery are complementary, not competing — surgery still produces larger and more durable loss at this BMI, and the right answer for many is a real conversation about both.

The options, side-by-side

GLP-1 drug options for people with a BMI of 40 or higher with trial evidence and fit notes.
DrugTrial evidenceFit note
Tirzepatide (Zepbound)SURMOUNT-1: −20.9% mean lossStrongest efficacy — usual first choice at BMI 40+
Semaglutide (Wegovy)STEP-1: −14.9%; SELECT CV outcomesChoose when cardiovascular risk reduction is a co-goal
Bariatric surgery (comparison, not a drug)Larger, more durable loss at severe obesityComplementary — worth a genuine discussion at this BMI
Tirzepatide (Zepbound, OSA indication)SURMOUNT-OSAIf sleep apnea is present — often an easier coverage route

Drug selection is a prescriber decision. This table summarizes the trial evidence — it is not a prescription or a substitute for clinical judgment.

What the trials show at severe obesity

Both pivotal trials enrolled patients across the obesity range including class III (BMI ≥40), and pre-specified analyses show percentage weight loss is broadly similar across BMI strata — a patient at BMI 45 loses a comparable percentage to one at BMI 32. Because the percentage applies to a larger starting weight, absolute pounds lost are higher.

Concretely: at a 300 lb starting weight, the SURMOUNT-1 tirzepatide mean (−20.9%) is roughly 63 lb, and the STEP-1 semaglutide mean (−14.9%) is roughly 45 lb. That is a substantial and clinically meaningful result. It is also, honestly, often not enough on its own to reach a BMI under 30 from a starting BMI of 45 — which is why the surgery conversation belongs on the table rather than being avoided.

GLP-1s versus bariatric surgery — the honest comparison

At severe obesity, bariatric surgery still produces larger and more durable weight loss than any current medication, with long-established outcome data. Presenting GLP-1s as a straightforward replacement for surgery at BMI 40+ overstates the evidence.

The realistic framing is complementary. Many patients use a GLP-1 to lose weight before surgery (which can reduce surgical risk), or after surgery to address regain, or instead of surgery after weighing the trade-offs — medication avoids an operation and is reversible, but requires indefinite ongoing treatment and cost, while surgery is a one-time procedure with surgical risk and permanent anatomical change.

The right answer depends on your comorbidities, prior attempts, surgical risk, and preferences. A prescriber who refuses to discuss surgery at BMI 40+, or a surgeon who dismisses medication, is each giving you half the picture.

Screen for the comorbidities that cluster at BMI 40+

Several conditions are common at severe obesity, frequently undiagnosed, and directly relevant to drug choice and coverage. Obstructive sleep apnea is the biggest one — highly prevalent at BMI 40+, and a diagnosis opens the Zepbound OSA indication, which many plans cover even when they exclude weight-loss drugs. Metabolic dysfunction-associated fatty liver disease (MASLD) is likewise common. Type 2 diabetes or prediabetes, hypertension, and dyslipidemia round out the cluster.

Getting these diagnosed is doubly valuable: they are worth treating in their own right, and each can be the documented comorbidity or alternate indication that unlocks coverage. If you snore loudly, wake unrefreshed, or have witnessed breathing pauses, ask for a sleep study before assuming a weight-loss-only coverage fight is your only path.

Dosing, side effects, and the long runway

Dosing follows the standard escalation (Wegovy 0.25→2.4 mg; Zepbound 2.5→up to 15 mg, each step ~4 weeks). At BMI 40+ most patients titrate to the higher maintenance doses, though the target is still set by response and tolerance rather than body size alone.

Set expectations for a long timeline. Reaching a meaningfully lower BMI from 40+ is a multi-year project, not a 68-week one — the trial curves flatten after roughly week 44-68, and further loss beyond that is slower. Planning for indefinite treatment, and for the muscle-protection work (protein 0.7-1.0 g/lb goal weight, resistance training twice weekly) that keeps the loss quality high, matters more here than in any lower-BMI group.

How to talk to your prescriber

Bring your BMI and weight history, any comorbidity diagnoses (especially a sleep study if you have one), prior weight-loss attempts, and your insurance card. At BMI 40+ you generally qualify on BMI alone, so the conversation is usually about which drug and which coverage route rather than whether you are eligible.

Useful questions: "Should we be discussing bariatric surgery alongside this?" "Do I have undiagnosed sleep apnea worth testing for?" "What is a realistic 1-year and 3-year target for me?" "How do we protect muscle over a long treatment course?" A prescriber who engages seriously with the surgery question is giving you better care, not selling you less.

Frequently asked

Which GLP-1 is best for BMI 40+?

Tirzepatide (Zepbound) has the strongest weight-loss evidence — −20.9% mean loss in SURMOUNT-1 versus −14.9% for semaglutide — making it the usual first choice at severe obesity. Semaglutide (Wegovy) is preferred when cardiovascular risk reduction is a co-goal, given the SELECT outcomes data.

Should I get bariatric surgery instead of a GLP-1 at BMI 40?

It is worth a genuine discussion rather than an either/or. Surgery still produces larger and more durable weight loss at severe obesity, but requires an operation and permanent anatomical change. Medication is reversible but needs indefinite ongoing treatment and cost. Many patients use a GLP-1 before surgery, after it, or instead of it — the right answer depends on your comorbidities, surgical risk, and preferences.

How much weight can I lose at BMI 40+?

Percentage loss is broadly similar across BMI strata, so absolute pounds are higher at a higher starting weight. At 300 lb, the trial means work out to roughly 63 lb on tirzepatide and 45 lb on semaglutide. Substantial and meaningful — though often not enough alone to reach a BMI under 30 from a starting BMI of 45.

Is coverage easier at BMI 40?

Generally yes. You clear the FDA threshold (BMI ≥30) with a wide margin and qualify on BMI alone without needing comorbidity documentation. Getting comorbidities like sleep apnea diagnosed can open additional, sometimes easier, coverage routes such as the Zepbound OSA indication.

Next steps

Other situations

Your situation may span more than one of these. Each guide reads the trial evidence for a different starting point.

Sources

This page describes published evidence and is not medical advice. GLP-1 drug selection is a decision for a licensed prescriber who has assessed you individually.

Best GLP-1 for BMI 40+ 2026 — Severe Obesity Evidence Review